2-[15-(4-aminobutyl)-9-(2-amino-2-oxoethyl)-27-butoxy-18-[hydroxy-(4-hydroxyphenyl)methyl]-6-(hydroxymethyl)-21-(1H-indol-3-ylmethyl)-2,5,8,11,14,17,20,23-octaoxo-25-(3,4,5-trihydroxyoxan-2-yl)oxy-1,4,7,10,13,16,19,22-octazacyclooctacos-3-yl]-2-hydroxyacetamide
| Internal ID | 3f8bc69d-72aa-41ab-b24d-e12f5657f8ca |
| Taxonomy | Organic acids and derivatives > Carboxylic acids and derivatives > Amino acids, peptides, and analogues > Peptides > Oligopeptides |
| IUPAC Name | 2-[15-(4-aminobutyl)-9-(2-amino-2-oxoethyl)-27-butoxy-18-[hydroxy-(4-hydroxyphenyl)methyl]-6-(hydroxymethyl)-21-(1H-indol-3-ylmethyl)-2,5,8,11,14,17,20,23-octaoxo-25-(3,4,5-trihydroxyoxan-2-yl)oxy-1,4,7,10,13,16,19,22-octazacyclooctacos-3-yl]-2-hydroxyacetamide |
| SMILES (Canonical) | |
| SMILES (Isomeric) | |
| InChI | InChI=1S/C54H78N12O20/c1-2-3-16-84-30-18-29(86-54-46(76)44(74)37(69)25-85-54)19-39(71)61-34(17-27-21-58-32-9-5-4-8-31(27)32)50(80)65-41(43(73)26-11-13-28(68)14-12-26)53(83)63-33(10-6-7-15-55)48(78)60-23-40(72)62-35(20-38(56)70)49(79)64-36(24-67)51(81)66-42(45(75)47(57)77)52(82)59-22-30/h4-5,8-9,11-14,21,29-30,33-37,41-46,54,58,67-69,73-76H,2-3,6-7,10,15-20,22-25,55H2,1H3,(H2,56,70)(H2,57,77)(H,59,82)(H,60,78)(H,61,71)(H,62,72)(H,63,83)(H,64,79)(H,65,80)(H,66,81) |
| InChI Key | VBWAMIXPRJDILL-UHFFFAOYSA-N |
| Popularity | 0 references in papers |
| Molecular Formula | C54H78N12O20 |
| Molecular Weight | 1215.30 g/mol |
| Exact Mass | 1214.54553292 g/mol |
| Topological Polar Surface Area (TPSA) | 530.00 Ų |
| XlogP | -4.90 |
| Atomic LogP (AlogP) | -7.06 |
| H-Bond Acceptor | 21 |
| H-Bond Donor | 19 |
| Rotatable Bonds | 19 |
| There are no found synonyms. |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.8763 | 87.63% |
| Caco-2 | - | 0.8656 | 86.56% |
| Blood Brain Barrier | - | 0.8750 | 87.50% |
| Human oral bioavailability | - | 0.6286 | 62.86% |
| Subcellular localzation | Nucleus | 0.3298 | 32.98% |
| OATP2B1 inhibitior | - | 0.8578 | 85.78% |
| OATP1B1 inhibitior | + | 0.8158 | 81.58% |
| OATP1B3 inhibitior | + | 0.9376 | 93.76% |
| MATE1 inhibitior | - | 0.9000 | 90.00% |
| OCT2 inhibitior | - | 0.8500 | 85.00% |
| BSEP inhibitior | + | 0.9249 | 92.49% |
| P-glycoprotein inhibitior | + | 0.7431 | 74.31% |
| P-glycoprotein substrate | + | 0.8743 | 87.43% |
| CYP3A4 substrate | + | 0.7526 | 75.26% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8337 | 83.37% |
| CYP3A4 inhibition | - | 0.8092 | 80.92% |
| CYP2C9 inhibition | - | 0.8874 | 88.74% |
| CYP2C19 inhibition | - | 0.8381 | 83.81% |
| CYP2D6 inhibition | - | 0.8423 | 84.23% |
| CYP1A2 inhibition | - | 0.8337 | 83.37% |
| CYP2C8 inhibition | + | 0.8311 | 83.11% |
| CYP inhibitory promiscuity | - | 0.7240 | 72.40% |
| UGT catelyzed | + | 0.7000 | 70.00% |
| Carcinogenicity (binary) | - | 0.9300 | 93.00% |
| Carcinogenicity (trinary) | Non-required | 0.6236 | 62.36% |
| Eye corrosion | - | 0.9892 | 98.92% |
| Eye irritation | - | 0.8979 | 89.79% |
| Skin irritation | - | 0.7760 | 77.60% |
| Skin corrosion | - | 0.9371 | 93.71% |
| Ames mutagenesis | - | 0.6000 | 60.00% |
| Human Ether-a-go-go-Related Gene inhibition | + | 0.7041 | 70.41% |
| Micronuclear | + | 0.7900 | 79.00% |
| Hepatotoxicity | - | 0.5698 | 56.98% |
| skin sensitisation | - | 0.8847 | 88.47% |
| Respiratory toxicity | + | 0.8000 | 80.00% |
| Reproductive toxicity | + | 0.9556 | 95.56% |
| Mitochondrial toxicity | + | 0.8750 | 87.50% |
| Nephrotoxicity | + | 0.5062 | 50.62% |
| Acute Oral Toxicity (c) | III | 0.6194 | 61.94% |
| Estrogen receptor binding | + | 0.7030 | 70.30% |
| Androgen receptor binding | + | 0.7274 | 72.74% |
| Thyroid receptor binding | + | 0.6224 | 62.24% |
| Glucocorticoid receptor binding | + | 0.6602 | 66.02% |
| Aromatase binding | + | 0.6468 | 64.68% |
| PPAR gamma | + | 0.7098 | 70.98% |
| Honey bee toxicity | - | 0.6537 | 65.37% |
| Biodegradation | - | 0.8000 | 80.00% |
| Crustacea aquatic toxicity | - | 0.5552 | 55.52% |
| Fish aquatic toxicity | + | 0.7566 | 75.66% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 99.97% | 91.11% |
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 99.88% | 83.82% |
| CHEMBL2581 | P07339 | Cathepsin D | 99.42% | 98.95% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 99.23% | 96.09% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 98.22% | 97.09% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 95.87% | 95.56% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 95.84% | 97.25% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 95.33% | 94.45% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 94.78% | 93.10% |
| CHEMBL4261 | Q16665 | Hypoxia-inducible factor 1 alpha | 94.50% | 85.14% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 94.23% | 97.64% |
| CHEMBL2035 | P08912 | Muscarinic acetylcholine receptor M5 | 94.01% | 94.62% |
| CHEMBL2996 | Q05655 | Protein kinase C delta | 93.99% | 97.79% |
| CHEMBL2288 | Q13526 | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | 93.29% | 91.71% |
| CHEMBL2373 | P21730 | C5a anaphylatoxin chemotactic receptor | 93.28% | 92.62% |
| CHEMBL3060 | Q9Y345 | Glycine transporter 2 | 92.61% | 99.17% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 92.25% | 92.88% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 91.94% | 90.08% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 91.69% | 88.56% |
| CHEMBL4581 | P52732 | Kinesin-like protein 1 | 91.10% | 93.18% |
| CHEMBL241 | Q14432 | Phosphodiesterase 3A | 89.08% | 92.94% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 88.71% | 89.00% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 88.57% | 95.89% |
| CHEMBL255 | P29275 | Adenosine A2b receptor | 88.34% | 98.59% |
| CHEMBL2072 | P35499 | Sodium channel protein type IV alpha subunit | 88.15% | 92.32% |
| CHEMBL211 | P08172 | Muscarinic acetylcholine receptor M2 | 88.08% | 94.97% |
| CHEMBL3038477 | P67870 | Casein kinase II alpha/beta | 86.61% | 99.23% |
| CHEMBL3476 | O15111 | Inhibitor of nuclear factor kappa B kinase alpha subunit | 86.44% | 95.83% |
| CHEMBL2535 | P11166 | Glucose transporter | 86.10% | 98.75% |
| CHEMBL213 | P08588 | Beta-1 adrenergic receptor | 85.70% | 95.56% |
| CHEMBL2635 | P51452 | Dual specificity protein phosphatase 3 | 85.33% | 94.00% |
| CHEMBL5043 | Q6P179 | Endoplasmic reticulum aminopeptidase 2 | 85.33% | 91.81% |
| CHEMBL4071 | P08311 | Cathepsin G | 85.10% | 94.64% |
| CHEMBL1293249 | Q13887 | Kruppel-like factor 5 | 85.06% | 86.33% |
| CHEMBL4296 | Q15858 | Sodium channel protein type IX alpha subunit | 84.71% | 96.11% |
| CHEMBL5896 | O75164 | Lysine-specific demethylase 4A | 84.26% | 99.09% |
| CHEMBL3401 | O75469 | Pregnane X receptor | 83.74% | 94.73% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 83.25% | 96.90% |
| CHEMBL4051 | P13569 | Cystic fibrosis transmembrane conductance regulator | 83.12% | 95.71% |
| CHEMBL299 | P17252 | Protein kinase C alpha | 83.09% | 98.03% |
| CHEMBL225 | P28335 | Serotonin 2c (5-HT2c) receptor | 82.79% | 89.62% |
| CHEMBL3830 | Q2M2I8 | Adaptor-associated kinase | 80.98% | 83.10% |
| CHEMBL6175 | Q9H3R0 | Lysine-specific demethylase 4C | 80.43% | 96.69% |
| CHEMBL4187 | Q99250 | Sodium channel protein type II alpha subunit | 80.22% | 95.50% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 80.14% | 97.14% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 80.11% | 95.00% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 163006699 |
| LOTUS | LTS0121370 |
| wikiData | Q104199206 |